MethylGene Inc.

MethylGene Inc.

May 25, 2006 10:00 ET

MethylGene Announces Two Oral Presentations Highlighting its Lead HDAC Inhibitor MCGD0103 at the American Society of Clinical Oncology Annual Meeting

MONTREAL, QUEBEC--(CCNMatthews - May 25, 2006) - MethylGene Inc. (TSX:MYG) will be presenting three abstracts, two of which are oral presentations, at the American Society of Clinical Oncology (ASCO) 2006 Annual Meeting held in Atlanta from June 2 to 6, 2006.

At the conference, two principle investigators involved in MethylGene's clinical trials will disclose preliminary and interim data for MGCD0103 in patients with leukemia or myelodysplastic syndromes (MDS) as well as data for patients treated with MGCD0103 who have advanced solid tumours. In addition, the Company will have an abstract published in the Proceedings on its clinical trial for MG98 in combination with interferon alpha in patients with advanced renal cell cancer.

The first oral presentation will be held on Saturday, June 3rd from 9:00am to 9:15am, eastern. Michael A. Carducci, MD, Associate Professor in Oncology and Urology Johns Hopkins Medical Institutions, will present "Phase I Study of Isotype-selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 Given as Three-times Weekly Oral Dose in Patients with Advanced Solid Tumors." The presentation will be held in Bldg. C, Level 3, Georgia Ballroom 3.

The second presentation will take place on Monday, June 5th from 3:30pm to 3:45pm, eastern. Guillermo Garcia-Manero, MD, Associate Internist and Associate Professor of Medicine, The University of Texas MD Anderson Cancer Centre, will present "Clinical Activity and Safety of the Histone Deacetylase Inhibitor MGCD0103: Results of a Phase I Study in Patients with Leukemia or Myelodysplastic Syndromes (MDS)." The presentation will be held at Bldg. C, Level 3, Georgia Ballroom 3.

About MethylGene

MethylGene is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious diseases. We intend to exploit our HDAC inhibitor technology in diseases other than cancer, such as diabetes, inflammation, fungal infections and neurodegenerative disorders. Two cancer product candidates are currently in clinical trials: MGCD0103, partnered with Pharmion Corporation and Taiho Pharmaceutical Co., Ltd., and MG98, partnered with MGI Pharma, Inc. MethylGene has an exclusive license agreement with Merck & Co. for the development and commercialization of small molecule beta-lactamase inhibitors to overcome antibiotic resistance. MethylGene has partnered its non-oncology HDAC program for neurodegenerative diseases with EnVivo Pharmaceuticals. MethylGene has a portfolio of preclinical programs for its multi-targeted kinase and histone deacetylase (HDAC) inhibitors for both oncology and non-oncology indications, and continues to seek partnering opportunities in these areas. Please visit our website at

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management of MethylGene, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene's control. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, which you are urged to read, as described in MethylGene's Annual Information Form for the fiscal year ending December 31, 2005, under the heading "risk factors," that can be found at Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation. These statements speak only as an update on the date they are made and MethylGene is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law.

Contact Information

  • MethylGene Inc.
    Andrea Gilpin, Ph.D, MBA
    Director, Investor Relations
    (514) 337-3333 ext. 416